Skip to main content
Caplight Logo









POLYGON Therapeutics

POLYGON Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.polygon.care/

Last Round

Seed

Nov 8, 2024

Total Funding Raised

$8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

POLYGON Therapeutics is a drug discovery company that provides a therapeutic development program to improve cardiovascular disease care and mitigate the damage inflicted on the heart.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

cardio-immunologyanti-CD8 monoclonal antibodymyocardial infarction treatmentimmunotherapymAbsheart attack treatmentpreclinical biotechcardiovascular diseasedrug developmentfirst-in-class therapeuticdisease-modifying therapeuticimmune response modulationCD8 T cell targetingreperfusion injurypharmaceutical licensingcell line developmentcontract development and manufacturing organizationCDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

POLYGON Therapeutics Comparables

Compare POLYGON Therapeutics with similar companies based on industry and business-model similarity.

POLYGON Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bitterroot Bio
81%
Beijing Sungen Biomedical Technology Co., Ltd.
78%
Cartio Therapeutics
76%

POLYGON Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 8, 2024
GrantApr 18, 2023
Pre SeedSep 8, 2022
GrantJul 7, 2022

Key People

Founding team and executive leadership

Hafid Ait-Oufella

Co-founder CMO & CSO

Founding Team

Tatiana Monseur

Co-Founder, COO & CFO

Founding Team

Mohamed ABOU ALI

Chief Executive Officer, Co-Founder

Founding Team

POLYGON Therapeutics Investors

Notable investors and investment history

POLYGON Therapeutics investors
InvestorRounds
AgoranovPre Seed
Région Île-de-FranceGrant
AudaciaSeed
Inserm TransfertPre Seed
EIT HealthSeed
Sorbonne VentureSeed
BpifranceGrant, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 363% MoM.

  • Jan 1, 2026

    Monthly visitors increased 42% MoM.

POLYGON Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

POLYGON Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about POLYGON Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range8
Year Founded2021
Last FundingNov 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?